CRTX - Cortexyme to start testing its lead candidate in Parkinson's disease

Cortexyme ([[CRTX]] +16.8%) says that based on interim analysis of GAIN Trial of its lead candidate atuzaginstat (COR388) in patients with mild-to-moderate Alzheimer's disease, the company announced pipeline expansion for 2021.Atuzaginstat will be evaluated in a new Phase 2 PEAK trial for Parkinson’s disease.Top-line data in 643 subject Alzheimer’s GAIN trial on schedule to be announced in Q4 2021. Enrollment into the U.S. GAIN open-label extension rollover to date has been approximately 90% of eligible participants. Enrollment expected to complete by Q4 2021.Also, top-line data for atuzaginstat in periodontal disease is planned in Q4 2021.Company's preclinical lysine gingipain inhibitor (COR588) is on track to enter the clinic in Q3 2021.CRTX ended the quarter with cash balance of $184.3M, projected to fund operations into 2023.

For further details see:

Cortexyme to start testing its lead candidate in Parkinson’s disease